Reply to: Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia"

Pediatr Blood Cancer. 2022 Nov;69(11):e29694. doi: 10.1002/pbc.29694. Epub 2022 Mar 26.

Authors

Meghan McCormick¹, Erika Friehling¹, Kenneth Smith²

Affiliations

¹ Department of Pediatrics, Hematology/Oncology Division, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
² Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

PMID: 35338677
DOI: 10.1002/pbc.29694

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents* / therapeutic use
Asparaginase / therapeutic use
Child
Cost-Benefit Analysis
Humans
Polyethylene Glycols / therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Premedication

Substances

Antineoplastic Agents
Polyethylene Glycols
pegaspargase
Asparaginase